Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 134

Similar articles for PubMed (Select 24950357)

1.

Serum IgG titres, but not avidity, correlates with neutralizing antibody response after H5N1 vaccination.

Pedersen GK, Höschler K, Øie Solbak SM, Bredholt G, Pathirana RD, Afsar A, Breakwell L, Nøstbakken JK, Raae AJ, Brokstad KA, Sjursen H, Zambon M, Cox RJ.

Vaccine. 2014 Jul 31;32(35):4550-7. doi: 10.1016/j.vaccine.2014.06.009. Epub 2014 Jun 18.

PMID:
24950357
2.

Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial.

Cox RJ, Pedersen G, Madhun AS, Svindland S, Sævik M, Breakwell L, Hoschler K, Willemsen M, Campitelli L, Nøstbakken JK, Weverling GJ, Klap J, McCullough KC, Zambon M, Kompier R, Sjursen H.

Vaccine. 2011 Oct 19;29(45):8049-59. doi: 10.1016/j.vaccine.2011.08.042. Epub 2011 Aug 22.

PMID:
21864624
3.

Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization.

Khurana S, Coyle EM, Dimitrova M, Castellino F, Nicholson K, Del Giudice G, Golding H.

PLoS One. 2014 Apr 22;9(4):e95496. doi: 10.1371/journal.pone.0095496. eCollection 2014.

4.

Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.

Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J.

Virology. 2008 Oct 25;380(2):412-20. doi: 10.1016/j.virol.2008.08.002. Epub 2008 Sep 10.

5.

DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults.

Khurana S, Wu J, Dimitrova M, King LR, Manischewitz J, Graham BS, Ledgerwood JE, Golding H.

J Infect Dis. 2013 Aug 1;208(3):413-7. doi: 10.1093/infdis/jit178. Epub 2013 Apr 30.

6.

The Madin-Darby canine kidney cell culture derived influenza A/H5N1 vaccine: a phase I trial in Taiwan.

Pan SC, Kung HC, Kao TM, Wu H, Dong SX, Hu MH, Chou AH, Chong P, Hsieh SM, Chang SC.

J Microbiol Immunol Infect. 2013 Dec;46(6):448-55. doi: 10.1016/j.jmii.2012.08.002. Epub 2012 Sep 27.

PMID:
23022464
7.

Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.

Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, Honorkiewicz A, Rock MT, Edwards KM, Del Giudice G, Rappuoli R, Golding H.

Sci Transl Med. 2010 Jan 20;2(15):15ra5. doi: 10.1126/scitranslmed.3000624.

8.

A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults.

Nagai H, Ikematsu H, Tenjinbaru K, Maeda A, Dramé M, Roman FP.

BMC Infect Dis. 2010 Nov 25;10:338. doi: 10.1186/1471-2334-10-338.

9.

Vaccination with drifted variants of avian H5 hemagglutinin protein elicits a broadened antibody response that is protective against challenge with homologous or drifted live H5 influenza virus.

Santiago FW, Fitzgerald T, Treanor JJ, Topham DJ.

Vaccine. 2011 Nov 8;29(48):8888-97. doi: 10.1016/j.vaccine.2011.09.069. Epub 2011 Sep 28.

10.

Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.

Nolan TM, Richmond PC, Skeljo MV, Pearce G, Hartel G, Formica NT, Höschler K, Bennet J, Ryan D, Papanaoum K, Basser RL, Zambon MC.

Vaccine. 2008 Aug 5;26(33):4160-7. doi: 10.1016/j.vaccine.2008.05.077. Epub 2008 Jun 13.

PMID:
18599164
11.

Oligomeric recombinant H5 HA1 vaccine produced in bacteria protects ferrets from homologous and heterologous wild-type H5N1 influenza challenge and controls viral loads better than subunit H5N1 vaccine by eliciting high-affinity antibodies.

Verma S, Dimitrova M, Munjal A, Fontana J, Crevar CJ, Carter DM, Ross TM, Khurana S, Golding H.

J Virol. 2012 Nov;86(22):12283-93. doi: 10.1128/JVI.01596-12. Epub 2012 Sep 5.

12.

Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus.

Ichinohe T, Ainai A, Ami Y, Nagata N, Iwata N, Kawaguchi A, Suzaki Y, Odagiri T, Tashiro M, Takahashi H, Strayer DR, Carter WA, Chiba J, Tamura S, Sata T, Kurata T, Hasegawa H.

J Med Virol. 2010 Oct;82(10):1754-61. doi: 10.1002/jmv.21824.

PMID:
20827774
13.

Unusual patterns of IgG avidity in some young children following two doses of the adjuvanted pandemic H1N1 (2009) influenza virus vaccine.

Yam KK, Gupta J, Brewer A, Scheifele DW, Halperin S, Ward BJ; Public Health Agency of Canada/Canadian Institute of Health Research, Influenza Research Network (PCIRN) Rapid Trial Study 3 (RT-03) Investigators.

Clin Vaccine Immunol. 2013 Apr;20(4):459-67. doi: 10.1128/CVI.00619-12. Epub 2013 Jan 23.

14.

The mucosal and systemic immune responses elicited by a chitosan-adjuvanted intranasal influenza H5N1 vaccine.

Svindland SC, Jul-Larsen Å, Pathirana R, Andersen S, Madhun A, Montomoli E, Jabbal-Gill I, Cox RJ.

Influenza Other Respir Viruses. 2012 Mar;6(2):90-100. doi: 10.1111/j.1750-2659.2011.00271.x. Epub 2011 Jul 12.

PMID:
21749672
15.

Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model.

Pedersen G, Major D, Roseby S, Wood J, Madhun AS, Cox RJ.

Influenza Other Respir Viruses. 2011 Nov;5(6):426-37. doi: 10.1111/j.1750-2659.2011.00256.x. Epub 2011 May 9.

PMID:
21668670
16.

Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults.

Gillard P, Chu DW, Hwang SJ, Yang PC, Thongcharoen P, Lim FS, Dramé M, Walravens K, Roman F.

BMC Infect Dis. 2014 Mar 15;14:142. doi: 10.1186/1471-2334-14-142.

17.

Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans.

Nachbagauer R, Wohlbold TJ, Hirsh A, Hai R, Sjursen H, Palese P, Cox RJ, Krammer F.

J Virol. 2014 Nov;88(22):13260-8. doi: 10.1128/JVI.02133-14. Epub 2014 Sep 10.

19.

Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.

Keitel W, Groth N, Lattanzi M, Praus M, Hilbert AK, Borkowski A, Tsai TF.

Vaccine. 2010 Jan 8;28(3):840-8. doi: 10.1016/j.vaccine.2009.10.019. Epub 2009 Oct 14.

PMID:
19835829
20.

Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets.

Layton RC, Petrovsky N, Gigliotti AP, Pollock Z, Knight J, Donart N, Pyles J, Harrod KS, Gao P, Koster F.

Vaccine. 2011 Aug 26;29(37):6242-51. doi: 10.1016/j.vaccine.2011.06.078. Epub 2011 Jul 6.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk